Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

We report the effectiveness of daratumumab, a human IgGκ monoclonal antibody targeting CD38 on plasma cells, for therapy-refractory antibody-mediated rejection (AMR) due to blood group antibodies in a 59-year-old man who received a living ABO-incompatible kidney transplantation. Standard treatment o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case Rep Nephrol Dial
Hlavní autoři: Spica, Davide, Junker, Till, Dickenmann, Michael, Schaub, Stefan, Steiger, Jürg, Rüfli, Tanja, Halter, Jörg, Hopfer, Helmut, Holbro, Andreas, Hirt-Minkowski, Patricia
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902247/
https://ncbi.nlm.nih.gov/pubmed/31828078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503951
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky